Daewon Pharmaceutical Co., Ltd

As of June 30, 2026, Daewon Pharmaceutical Co., Ltd carries a market capitalization of 168.25B, placing it among publicly traded companies globally. Its enterprise value stands at 299.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Daewon Pharmaceutical Co., Ltd's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Daewon Pharmaceutical Co., Ltd has 21.43M shares outstanding.

As of June 30, 2026, Daewon Pharmaceutical Co., Ltd trades at a trailing price-to-earnings ratio of 63.92. The price-to-sales ratio is 0.27, and the price-to-book ratio stands at 0.63.

As of June 30, 2026, Daewon Pharmaceutical Co., Ltd trades at an EV/EBITDA multiple of 12.24 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 299.27B versus a market cap of 168.25B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Daewon Pharmaceutical Co., Ltd maintains a current ratio of 1.12, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.60, indicating elevated leverage, while an interest coverage ratio of 3.62 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Daewon Pharmaceutical Co., Ltd posted a return on equity (ROE) of 0.98, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.01, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.45, useful for judging operating efficiency across full business cycles. The company generates approximately 457.06M in revenue per employee across its workforce of 1,344.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.05 indicates how many times Daewon Pharmaceutical Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Daewon Pharmaceutical Co., Ltd recorded 6.76B in income tax expense. That works out to an effective tax rate of 74.63, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 9.05B, leaving 2.63B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Daewon Pharmaceutical Co., Ltd's stock has declined approximately 39.16% over the past 52 weeks. The 50-day moving average sits at 7,917.80, while the 200-day moving average is 9,470.35.

Over the twelve months ended June 30, 2026, Daewon Pharmaceutical Co., Ltd generated 614.64B in revenue and converted that into 2.63B in net income, yielding earnings per share of 105.15. EBITDA reached 24.45B, while operating income came in at -66.20M.

As of June 30, 2026, Daewon Pharmaceutical Co., Ltd holds 66.18B in cash and equivalents against 189.15B in total debt, resulting in a net debt position of 160.71B. Total book value stands at 267.68B, with working capital of 25.69B providing operational flexibility.

Daewon Pharmaceutical Co., Ltd produced 18.18B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -38.15B in capital expenditures, free cash flow totaled -19.97B - equivalent to -931.77 per share.

Over the twelve months ended June 30, 2026, Daewon Pharmaceutical Co., Ltd posted a gross margin of 45.66, reflecting its pricing power and cost economics. The operating margin of -0.01 and net profit margin of 0.43 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Daewon Pharmaceutical Co., Ltd paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -11.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Daewon Pharmaceutical Co., Ltd shareholders.

Daewon Pharmaceutical Co., Ltd's most recent stock split took place on March 7, 2022 with a 100:103 split ratio.

As of June 30, 2026, Daewon Pharmaceutical Co., Ltd has an Altman Z-Score of 2.32, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.